The FDA Guidance Documents and other regulatory guidance can be downloaded from FDA's website. Below is an example of the first 8 listings when you search FDA's website for FDA Guidance Documents/compounding.
This feature is provided to give a convenient way to search for all FDA guidance documents from a single location.
If you cannot find the document you're looking for here, you can browse separate collections of guidance documents by topic.
Summary | Document | Issue Date | FDA Organization | Topic | Guidance Status | Open for Comment | Comment Closing Date on Draft | Docket Number |
CVM GFI #256-Compounding Animal Drugs from Bulk Drug Substances | PDF (404.91) KB) | 8/10/2022 | Center for Veterinary Medicine | Compounding | Final | No | 10/15/2020 | FDA-2018-D-4533 |
Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry | PDF (122.11 KB) | 10/6/2021 | Center for Drug Evaluation and Research | Compounding | Draft | No | | FDA-2016-D-0271 |
Insanitary Conditions at Compounding Facilities Guidance for Industry | PDF (123.19 KB) | 11/6/2020 | Center for Drug Evaluation and Research | Administrative / Procedural, Compounding | Final | No | | FDA-2016-D-2268 |
Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency Guidance for Industry: Guidance for Industry | PDF (76.64 KB) | 4/20/2020 | Center for Drug Evaluation and Research | Compliance, Compounding | Final | No | | FDA-2020-D-1136 |
Temporary Policy for Compounding of Certain Drugs for Hospitalized Patients by Outsourcing Facilities During the COVID-19 Public Health Emergency | PDF (208.46 KB) | 4/16/2020 | Center for Drug Evaluation and Research | Compounding | Final | No | | FDA-2020-D-1136 |
Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act | PDF (172.27 KB) | 4/3/2020 | Center for Drug Evaluation and Research | User Fees, Compounding | Final | No | | FDA-2014-D-0329 |
Current Good Manufacturing Practice-Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry | PDF (484.69 KB) | 1/22/2020 | Center for Drug Evaluation and Research | Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP) | Draft | No | 2/11/2019 | FDA-2014-D-0779 |
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients with Te-trahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry | PDF (77.61 KB) | 7/8/2019 | Center for Drug Evaluation and Research | Compounding | Final | No | | FDA-2019-D-2733 |
Continued next week.